The COVID-19 pandemic has significantly impacted the way of life worldwide and continues to bring high mortality rates to at-risk groups. Patients who develop severe COVID-19 pneumonia, often complicated with ARDS, are left with limited treatment options with no targeted therapy currently available. One of the features of COVID-19 is an overaggressive immune reaction that leads to multiorgan failure. Mesenchymal stromal cell (MSC) treatment has been in development for various clinical indications for over a decade, with a safe side effect profile and promising results in preclinical and clinical trials. Therefore, the use of MSCs in COVID-19-induced respiratory failure and ARDS was a logical step in order to find a potential treatment option for the most severe patients. In this review, the main characteristics of MSCs, their proposed mechanism of action in COVID-19 treatment and the effect of this therapy in published case reports and clinical trials are discussed.

中文翻译：

---

间充质基质细胞：COVID-19 治疗的潜在选择

COVID-19 大流行严重影响了全世界的生活方式，并继续给高危人群带来高死亡率。患有严重 COVID-19 肺炎且通常并发 ARDS 的患者的治疗选择有限，目前没有可用的靶向治疗。COVID-19 的特征之一是过度的免疫反应，导致多器官衰竭。间充质基质细胞 (MSC) 治疗已针对各种临床适应症进行了十多年的开发，具有安全的副作用特征并在临床前和临床试验中取得了有希望的结果。因此，在 COVID-19 引起的呼吸衰竭和 ARDS 中使用 MSC 是为最严重的患者找到潜在治疗选择的合乎逻辑的步骤。在这篇综述中，MSCs的主要特征，